STONY BROOK, NY / ACCESSWIRE / December 5, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and full year financial results 2023 ended September 30, 2023, on Thursday, December 7, 2023, after the market close. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. ET.
Date & Time: Thursday, December 7 @ 4:30 p.m. ET
Dial In:
A replay of the conference call will be available for 7 days following the conclusion of the call:
An accompanying slide presentation will be embedded in the webcast (live and replay) and can be accessed under the 'News & Events' tab and ‘Company Events' section of the Applied DNA investor relations website at https://investors.adnas.com/
The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, through our recent acquisition of Spindle Biotech, Inc. ("Spindle"), the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.
The Company's common stock is listed on NASDAQ under ticker symbol 'APDN,' and its publicly traded warrants are listed on OTC under ticker symbol 'APPDW.'
For additional information:
Investor Relations: Sanjay M. Hurry, 917-733-5573, This email address is being protected from spambots. You need JavaScript enabled to view it.
Web: www.adnas.com
Twitter: @APDN
| Last Trade: | US$5.51 |
| Daily Volume: | 0 |
| Market Cap: | US$7.110M |
September 29, 2025 September 23, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
